vs
Side-by-side financial comparison of Evercore Inc. (EVR) and BeOne Medicines Ltd. (ONC). Click either name above to swap in a different company.
BeOne Medicines Ltd. is the larger business by last-quarter revenue ($1.5B vs $1.3B, roughly 1.2× Evercore Inc.). Evercore Inc. runs the higher net margin — 15.7% vs 4.4%, a 11.3% gap on every dollar of revenue. On growth, BeOne Medicines Ltd. posted the faster year-over-year revenue change (32.8% vs 32.4%). Evercore Inc. produced more free cash flow last quarter ($798.6M vs $379.8M). Over the past eight quarters, Evercore Inc.'s revenue compounded faster (48.9% CAGR vs 41.2%).
Evercore Inc., formerly known as Evercore Partners, is a global independent investment banking advisory firm founded in 1995 by Roger Altman, David Offensend, and Austin Beutner. The firm has advised on over $4.7 trillion of merger, acquisition, and restructuring transactions since its founding.
BeOne Medicines Ltd.ONCEarnings & Financial Report
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
EVR vs ONC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $1.5B |
| Net Profit | $204.0M | $66.5M |
| Gross Margin | — | 90.5% |
| Operating Margin | 24.2% | 12.4% |
| Net Margin | 15.7% | 4.4% |
| Revenue YoY | 32.4% | 32.8% |
| Net Profit YoY | 45.2% | 143.8% |
| EPS (diluted) | $4.80 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.3B | $1.5B | ||
| Q3 25 | $1.0B | $1.4B | ||
| Q2 25 | $838.0M | $1.3B | ||
| Q1 25 | $699.0M | $1.1B | ||
| Q4 24 | $979.5M | $1.1B | ||
| Q3 24 | $738.4M | $1.0B | ||
| Q2 24 | $693.4M | $929.2M | ||
| Q1 24 | $585.0M | $751.7M |
| Q4 25 | $204.0M | $66.5M | ||
| Q3 25 | $144.6M | $124.8M | ||
| Q2 25 | $97.2M | $94.3M | ||
| Q1 25 | $146.2M | $1.3M | ||
| Q4 24 | $140.4M | $-151.9M | ||
| Q3 24 | $78.4M | $-121.3M | ||
| Q2 24 | $73.8M | $-120.4M | ||
| Q1 24 | $85.7M | $-251.2M |
| Q4 25 | — | 90.5% | ||
| Q3 25 | — | 86.1% | ||
| Q2 25 | — | 87.5% | ||
| Q1 25 | — | 85.2% | ||
| Q4 24 | — | 85.8% | ||
| Q3 24 | — | 83.0% | ||
| Q2 24 | — | 85.1% | ||
| Q1 24 | — | 83.4% |
| Q4 25 | 24.2% | 12.4% | ||
| Q3 25 | 20.8% | 11.5% | ||
| Q2 25 | 18.0% | 6.7% | ||
| Q1 25 | 16.0% | 1.0% | ||
| Q4 24 | 21.8% | -7.0% | ||
| Q3 24 | 16.7% | -12.0% | ||
| Q2 24 | 15.9% | -11.5% | ||
| Q1 24 | 14.8% | -34.8% |
| Q4 25 | 15.7% | 4.4% | ||
| Q3 25 | 13.8% | 8.8% | ||
| Q2 25 | 11.6% | 7.2% | ||
| Q1 25 | 20.9% | 0.1% | ||
| Q4 24 | 14.3% | -13.5% | ||
| Q3 24 | 10.6% | -12.1% | ||
| Q2 24 | 10.6% | -13.0% | ||
| Q1 24 | 14.6% | -33.4% |
| Q4 25 | $4.80 | $0.05 | ||
| Q3 25 | $3.41 | $0.08 | ||
| Q2 25 | $2.36 | $0.06 | ||
| Q1 25 | $3.48 | $0.00 | ||
| Q4 24 | $3.32 | $-0.10 | ||
| Q3 24 | $1.86 | $-0.09 | ||
| Q2 24 | $1.81 | $-0.09 | ||
| Q1 24 | $2.09 | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.0B | $4.5B |
| Total DebtLower is stronger | — | $836.4M |
| Stockholders' EquityBook value | $2.0B | $4.4B |
| Total Assets | $5.4B | $8.2B |
| Debt / EquityLower = less leverage | — | 0.19× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.0B | $4.5B | ||
| Q3 25 | $2.4B | $4.0B | ||
| Q2 25 | $1.7B | $2.8B | ||
| Q1 25 | $1.4B | $2.5B | ||
| Q4 24 | $2.4B | $2.6B | ||
| Q3 24 | $1.8B | $2.7B | ||
| Q2 24 | $1.7B | $2.6B | ||
| Q1 24 | $1.4B | $2.8B |
| Q4 25 | — | $836.4M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $2.0B | $4.4B | ||
| Q3 25 | $1.8B | $4.1B | ||
| Q2 25 | $1.7B | $3.8B | ||
| Q1 25 | $1.5B | $3.5B | ||
| Q4 24 | $1.7B | $3.3B | ||
| Q3 24 | $1.6B | $3.4B | ||
| Q2 24 | $1.5B | $3.4B | ||
| Q1 24 | $1.4B | $3.4B |
| Q4 25 | $5.4B | $8.2B | ||
| Q3 25 | $4.4B | $7.6B | ||
| Q2 25 | $3.7B | $6.3B | ||
| Q1 25 | $3.3B | $5.8B | ||
| Q4 24 | $4.2B | $5.9B | ||
| Q3 24 | $3.6B | $5.8B | ||
| Q2 24 | $3.3B | $5.7B | ||
| Q1 24 | $3.0B | $5.7B |
| Q4 25 | — | 0.19× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $807.5M | $417.3M |
| Free Cash FlowOCF − Capex | $798.6M | $379.8M |
| FCF MarginFCF / Revenue | 61.6% | 25.4% |
| Capex IntensityCapex / Revenue | 0.7% | 2.5% |
| Cash ConversionOCF / Net Profit | 3.96× | 6.28× |
| TTM Free Cash FlowTrailing 4 quarters | $1.2B | $941.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $807.5M | $417.3M | ||
| Q3 25 | $560.9M | $402.6M | ||
| Q2 25 | $437.7M | $263.6M | ||
| Q1 25 | $-549.7M | $44.1M | ||
| Q4 24 | $686.4M | $75.2M | ||
| Q3 24 | $234.5M | $188.4M | ||
| Q2 24 | $348.5M | $-95.6M | ||
| Q1 24 | $-281.2M | $-308.6M |
| Q4 25 | $798.6M | $379.8M | ||
| Q3 25 | $541.5M | $354.5M | ||
| Q2 25 | $411.7M | $219.8M | ||
| Q1 25 | $-569.3M | $-12.3M | ||
| Q4 24 | $673.1M | $-17.3M | ||
| Q3 24 | $226.6M | $54.7M | ||
| Q2 24 | $340.7M | $-205.5M | ||
| Q1 24 | $-282.3M | $-465.1M |
| Q4 25 | 61.6% | 25.4% | ||
| Q3 25 | 51.8% | 25.1% | ||
| Q2 25 | 49.1% | 16.7% | ||
| Q1 25 | -81.4% | -1.1% | ||
| Q4 24 | 68.7% | -1.5% | ||
| Q3 24 | 30.7% | 5.5% | ||
| Q2 24 | 49.1% | -22.1% | ||
| Q1 24 | -48.3% | -61.9% |
| Q4 25 | 0.7% | 2.5% | ||
| Q3 25 | 1.9% | 3.4% | ||
| Q2 25 | 3.1% | 3.3% | ||
| Q1 25 | 2.8% | 5.0% | ||
| Q4 24 | 1.4% | 8.2% | ||
| Q3 24 | 1.1% | 13.3% | ||
| Q2 24 | 1.1% | 11.8% | ||
| Q1 24 | 0.2% | 20.8% |
| Q4 25 | 3.96× | 6.28× | ||
| Q3 25 | 3.88× | 3.22× | ||
| Q2 25 | 4.50× | 2.79× | ||
| Q1 25 | -3.76× | 34.71× | ||
| Q4 24 | 4.89× | — | ||
| Q3 24 | 2.99× | — | ||
| Q2 24 | 4.72× | — | ||
| Q1 24 | -3.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EVR
| Advisory Fees | $1.1B | 87% |
| Commissions And Related Revenue | $66.5M | 5% |
| Underwriting Fees | $49.5M | 4% |
| Other | $29.6M | 2% |
| Investment Management | $23.2M | 2% |
ONC
Segment breakdown not available.
